Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Firebrick Pharma Limited ( (AU:FRE) ) has provided an update.
Firebrick Pharma Limited held its Annual General Meeting where all resolutions, including the special resolution for the approval of the 7.1A Mandate, were passed. This successful meeting indicates strong shareholder support and positions the company for continued growth and expansion in its market, potentially benefiting stakeholders through enhanced market presence and product offerings.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has introduced Nasodine® Nasal Spray in markets such as the United States, Singapore, and Fiji & South Pacific, with plans for expansion into the Philippines. Additionally, Firebrick is preparing to launch its new product, Nasodine Throat Spray, in Singapore.
Average Trading Volume: 84,699
Technical Sentiment Signal: Sell
Current Market Cap: A$15.85M
Find detailed analytics on FRE stock on TipRanks’ Stock Analysis page.